Novel process for preparation of darunavir and darunavir ethanolate of fine particle size

ABSTRACT

The present invention provides a novel process for preparation of darunavir that involves reduction of [(1S,2R)-3-[[(4-nitrophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, of formula (5). The present invention also provides darunavir ethanolate of particle size wherein d 0.9  is less than 130 μm, d 0.5  is less than 30 μm, d 0.1  is less than 10 μm and process for its preparation.

This application is a Divisional application of U.S. application Ser.No. 13/505,148 filed 30 Apr. 2012, which is a National Stage Applicationof PCT/IN2010/000714, filed 1 Nov. 2010, which claims benefit of SerialNo. 1000/KOL/2010, filed 9 Sep. 2010 in India, and which also claimsbenefit of Serial No. 1303/KOL/2009, filed 30 Oct. 2009 in India andwhich applications are incorporated herein by reference. To the extentappropriate, a claim of priority is made to each of the above disclosedapplications.

TECHNICAL FIELD OF THE INVENTION

The present invention provides a novel process for preparation ofdarunavir that involves reduction of[(1S,2R)-3-[[(4-nitrophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamicacid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, of formula(5).The present invention is also related to darunavir ethanolate offine particle size and process for its preparation.

BACKGROUND OF THE INVENTION

Darunavir is a potent HIV protease inhibitor belonging to the class ofhydroxyethyl amino sulfonamides. Darunavir is known by chemical name[(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamicacid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester. Darunavir isgenerically disclosed in U.S. Pat. No. 5,843,946 and specificallydisclosed in U.S. Pat. No. 6,248,775.

The ethanol solvate of darunavir, referred as Darunavir ethanolate isrepresented by following structure:

Darunavir ethanolate is marketed in USA by Tibotec Pharmaceuticals underthe trade name Prezista® and is specifically covered by U.S. Pat. No.7,700,645.

We observed that very few references are directed towards synthesis ofdarunavir. The product patent U.S. Pat. No. 6,248,775 B2 does notprovide any enabling disclosure for preparation of darunavir (1).

The process described in the publication Dominique et. al; Journal ofMedicinal Chemistry, 2005, 48(6), 1813-1822 and the patent applicationUS 2007/060642 A1 which involves condensation of diamino compound (2)with furanyl derivative (3) is most relevant to the present inventionand is depicted in scheme 1 below.

The synthesis of darunavir (1) by coupling of diamino compound (2) withfuranyl derivative (3) very likely leads to formation of impurities,viz., impurity A and impurity B. However, the formation of theseimpurities A and B is not mentioned in any of the prior art references.The structural formulae of impurity A and impurity B are as representedbelow:

These impurities can form due to presence of 4-amino group in the4-aminophenylsulfonyl group on the tertiary nitrogen of diamino compound(2), since it can react with furanyl derivative (3). Due to prevalenceof these impurities the process of above mentioned prior art is lessdesired and there is a need to develop an improved process.

The publication Dominique et. al; Journal of Medicinal Chemistry, 2005,48(6), 1813-1822 further discloses preparation of nitro compound (5) byreaction of amino compound (4) with furanyl derivative (3) (whereR=succinimidyl group) in presence of triethylamine in tetrahydrofuran toobtain nitro compound (5). Surprisingly, this publication does notprovide any suggestions for reduction of nitro compound (5) to obtaindarunavir (1). The process disclosed in this publication is depicted inthe synthetic scheme 2.

The inventors of the present invention have developed a novel process,which not only avoids formation of impurities A and B but also performsreduction of nitro compound (5) under selective condition in such a waythat decomposition of carbamate linkage occurs to a lesser extent.

It is well known that particle size can affect the solubility propertiesof a pharmaceutical compound. Particle size reduction can increase acompound's dissolution rate and consequently its bioavailability.Particle size can affect how freely the crystals or powdered form of thedrug will flow past each other, which has consequence in productionprocess of pharmaceutical products containing the drug. The inventors ofthe present invention have developed darunavir ethanolate of fineparticle size, which has good solubility and is well suited forpreparing pharmaceutical products.

SUMMARY OF THE INVENTION

The present invention provides a novel process for preparation ofdarunavir of formula (1), comprising the steps of:

-   -   (i) condensation of the amino compound of formula (4) with        furanyl derivative (3) to obtain nitro compound of formula (5);    -   (ii) reduction of nitro compound of formula (5) to obtain        darunavir; and    -   (iii) optionally converting darunavir to darunavir ethanolate.

The present invention also provides darunavir ethanolate of particlesize wherein d_(0.9) is less than 130 μm, d_(0.5) is less than 30 μm andd_(0.1) is less than 10 μm. The present invention further provides aprocess for preparation of darunavir ethanolate of fine particle sizecomprising the steps of:

-   -   (i) feeding darunavir ethanolate to milling chamber under        nitrogen pressure;    -   (ii) rotating the milling chamber; and    -   (iii) collecting the smaller size particles.

DESCRIPTION OF THE INVENTION

The present invention provides a novel process for preparation ofdarunavir of formula (1)

comprising the steps of:

-   -   (i) condensation of the amino compound of formula (4)

with furanyl derivative of formula (3)

where R=succinimidyl, p-nitrophenyl, imidazolyl, phenyl, chloro or thelike, to obtain nitro compound of formula (5);

-   -   (ii) reduction of nitro compound of formula (5) to obtain        darunavir (1); and    -   (iii) optionally converting darunavir (1) to darunavir        ethanolate.

The process of present invention is depicted in scheme 3 given below

The starting compound (4) can be obtained by the methods known in U.S.Pat. No. 6,248,775 B2 and US 2007/060642 A1. The furanyl derivative (3)is obtained by reaction of (3R,3aS,6aR) hexahydrofuro[2,3-b]furan-3-olof formula (6)

with succinimidyl carbonate, bis (4-nitrophenyl) carbonate, diimidazolecarbonate, ter-butyloxycarbonyl anhydride, phenyl chloroformate,p-nitrophenyl chloroformate, phosgene etc.

The compound (3R,3aS,6aR) hexahydrofuro[2,3-b]furan-3-ol (6) employedfor preparation of furanyl derivative (3) can be obtained by methodsdescribed in literature such as U.S. Pat. No. 6,919,465; WO 2008/055970A2; WO 2005/095410 A1; WO 03/022853 A1; Dominique et. al, Journal ofMedicinal Chemistry, (2005), 48(6), 1813-1822; Ghosh et. al, Journal ofOrganic Chemistry, (2004), 69(23), 7822-7829; Ghosh et. al, Journal ofMedicinal Chemistry, (1996), 39, 3278-3290; Ghosh et. al; TetrahedronLetters, (1995), 36(4), 505-508.

In one embodiment, the present invention provides a process forpreparation of darunavir by carrying out coupling of the amino compound(4) with furanyl derivative (3) in a solvent or mixture of solvents inpresence of a base to obtain the nitro compound (5).

The molar equivalent of furanyl derivative (3) with respect to aminocompound (4) is in the range of 0.8 to 3, preferably 1.0 to 1.2.

The coupling is carried out in a solvent selected from lower alcoholssuch as methanol, ethanol, n-propanol, isopropanol; ketones such asacetone, ethylmethyl ketone, diethyl ketone, methylisobutyl ketone;lower aliphatic esters such as ethyl acetate, methyl acetate;halogenated hydrocarbons such as dichloromethane, chloroformdichloroethane; dimethylformamide, dimethyl sulfoxide, acetonitrile,water or mixtures thereof. Most preferably dichloromethane is used as asolvent for coupling reaction.

The coupling reaction is carried out in presence of an organic orinorganic base. The organic base is selected from triethylamine,diisopropylethyl amine, pyridine and the like while inorganic base isselected from hydroxides of alkali metals or alkaline earth metals suchas sodium hydroxide, potassium hydroxide, lithium hydroxide;bicarbonates of alkali metals or alkaline earth metals such as sodiumbicarbonate, potassium bicarbonate and the like; carbonates of alkalimetals or alkaline earth metals such as sodium carbonate, potassiumcarbonate; ammonia or the like. Most preferably triethylamine is used asa base.

The molar ratio of base with respect to amino compound (4) is in therange of 0.5 to 6 molar equivalents, more preferably 1 to 3 molarequivalents, most preferably 2 molar equivalents.

The coupling reaction is carried out at a temperature ranging from −20°C. to 100° C., more preferably in range of 0° C. to 50° C., mostpreferably at 20-30° C.

In another preferred embodiment, the present invention provides a novelprocess for reduction of the nitro compound (5) in an organic solvent ormixture of solvents in presence of a transition metal catalyst to obtaindarunavir.

Solvent suitable for reduction of the nitro compound (5) may be selectedfrom lower alcohols such as methanol, ethanol, isopropyl alcohol,ter-butyl alcohol; aliphatic esters such as ethyl acetate, methylacetate, isopropyl acetate; amides such as dimethyl formamide; aliphatichalogenated hydrocarbons such as dichloromethane, chloroform; aromatichydrocarbons such as benzene, xylene, toluene; ethers such as diethylether, diisopropyl ether, tetrahydrofuran, 1,4-dioxane;dimethylsulfoxide, water or any mixtures thereof. More preferably esterssuch as ethyl acetate, methyl acetate, isopropyl acetate are used, mostpreferably ethyl acetate is employed.

The catalyst employed for reduction is selected from transition metalcatalyst such as palladium on carbon, PtO₂, Raney Nickel, ruthenium,rhodium; iron in acidic medium; borane complexes, diborane; borohydridessuch as sodium borohydride, lithium aluminium hydride and the like.

The reduction of the nitro compound (5) is more preferably carried outby catalytic hydrogenation in presence of transition metal catalystselected from palladium on carbon, PtO₂ and Raney nickel. Palladium oncarbon is most preferred amongst these.

The hydrogenation is carried out at a temperature ranging from −20° C.to 100° C., more preferably in range of 0° C. to 50° C., most preferablyat 20-30° C.

The reduction of nitro moiety is optionally carried out in presence ofan organic or inorganic base. The organic base is selected fromtriethylamine, diisopropylethyl amine, pyridine and the like whileinorganic base is selected from hydroxides of alkali metals or alkalineearth metals such as sodium hydroxide, potassium hydroxide, lithiumhydroxide; bicarbonates of alkali metals or alkaline earth metals suchas sodium bicarbonate, potassium bicarbonate and the like; carbonates ofalkali metals or alkaline earth metals such as sodium carbonate,potassium carbonate; ammonia or mixtures thereof. Most preferablytriethylamine is used as a base.

The molar ratio of base with respect to nitro compound (5) is in therange of 0.5 to 5 molar equivalents, more preferably 1 to 3 molarequivalents, most preferably 1.5 molar equivalents.

The process of present invention has following advantages over the priorart method:

-   -   1. It employs condensation of amino compound (4) with the        furanyl derivative (3), which avoids formation of impurity A and        impurity B.    -   2. The reduction of nitro compound (5) by catalytic        hydrogenation is preferably carried out in basic condition,        which prevents cleavage of the carbamate linkage.    -   3. Better yield of darunavir.    -   4. Enhanced purity of darunavir.

In another aspect the invention provides darunavir ethanolate havingparticle size wherein d_(0.5) is less than 30 μm.

In yet another aspect the invention provides darunavir ethanolate havingparticle size wherein d_(0.9) is less than 130 μm and d_(0.5) is lessthan 30 μm.

In yet another aspect the invention provides darunavir ethanolate havingparticle size wherein d_(0.9) is less than 130 82 m, d_(0.5) is lessthan 30 μm and d_(0.1) is less than 10 μm.

Comminution of darunavir ethanolate may be performed by any of the knownmethods of particle size reduction. The principal operations ofconventional size reduction are milling of a feedstock material andsorting of the milled material by size.

Micronization is carried out by known methods such as jet milling, mediamilling, pulverization and the like. Preferably micronization is carriedout in a jet mill type micronizer.

In another embodiment, the present invention provides a process forpreparation of darunavir ethanolate having fine particle size comprisingthe steps of:

-   -   (i) feeding darunavir ethanolate to milling chamber under        nitrogen pressure;    -   (ii) rotating the milling chamber; and    -   (iii) collecting the smaller particles.

Darunavir ethanolate employed could be in the form of crystals, powderedaggregates and coarse powder of either crystalline or amorphous form.

All the steps of above mentioned micronization process are performed atambient temperature. The feedstock of solid particles of darunavirethanolate is tangentially fed in to the circular milling chamber.Milling chamber is rotated at a speed of 10-50 rpm, more preferably at20-30 rpm for a time period of 1-10 hours, preferably for 3-7 hours.Milling chamber is supplied with nitrogen under pressure ofapproximately 1-5 Kg/cm², more preferably 2-3 Kg/cm². The particles areaccelerated in a spiral movement in the milling chamber by number ofangular holes in the ring and deposited on the periphery of the chamber.The milling action takes place due to high velocity of nitrogen. Largerparticles get retained at the periphery due to centrifugal force andsmaller particles travel along with the exhaust nitrogen through centralport and get collected in the collection chamber.

The particle size of the darunavir ethanolate obtained by the process ofpresent invention can be determined by any method known in the art suchas laser diffraction, sieve analysis, microscope observation,sedimentation etc. Malvern mastersizer is an instrument employed forparticle size determination in the present invention.

The invention is further defined by reference to the following examples.It is apparent to those skilled in the art that many modifications, bothto materials and methods, may be practiced without departing from scopeof the invention.

Example 1 Preparation of Nitro Compound (5)

The solution of 3.5 g (0.013 mol) of furanyl derivative (3) in a mixtureof 50 ml of dichloromethane and 50 ml of acetonitrile was cooled to 0-5°C. and 1.98 ml (0.014 mol) of triethylamine was added. To the mixture 5g (0.011 mol) of amino compound (4) was added and stirred for 1 hour.The reaction mixture was warmed to room temperature. To the reactionmixture 0.2 g of 40% aqueous solution of methyl amine was added and washeated till completion of the reaction. The reaction mixture was washedtwice with 10% sodium carbonate solution (25 ml×2) and layers wereseparated. The organic layer was washed with water, dried over sodiumsulfate and evaporated to dryness under vacuum. The residue wasrecrystallized from 50 ml ethanol and dried under vacuum at 40-45° C.

Yield=5.8 g

Example 2 Preparation of Darunavir

The solution of 5 g (0.009 mol) of nitro compound (5) in 100 ml of ethylacetate was prepared by warming and cooled to room temperature. To thesolution 2.5 ml (0.018 mol) of triethylamine and 0.5 g of 10% Pd/C (50%wet) were added. Hydrogenation was carried out at 3 Kg pressure for 1-2hours at room temperature. Catalyst was filtered off and washed with 10ml ethyl acetate. Solvent was evaporated under reduced pressure toobtain residue. To the residue 110 ml isopropyl alcohol was added andheated to 70-75° C. to obtain clear solution. It was cooled to roomtemperature and stirred for 1 hour. The crystals obtained were filtered,washed with isopropyl alcohol and dried under vacuum.

Yield=4.7 g

Example 3 Preparation of Darunavir Ethanolate

100 gm of darunavir was dissolved in 1000 ml of denatured ethanol(mixture of 97% ethanol and 3% toluene) at 70-75° C. to obtain clearsolution. 5 gm of activated charcoal was added and stirred for 120-150minutes. The hot solution was filtered through hyflow bed and the bedwas washed with 100 ml ethanol. The solution was filtered again through0.2μ filter maintaining temperature at 70-75° C. The reaction mass wascooled to 15-20° C., stirred for an hour and filtered. The wet cake waswashed with 100 ml of chilled ethanol and dried under vacuum at 40-45°C. to afford 89.5 gm of off white colored crystalline solid.

Example 4 Preparation of Darunavir Ethanolate of Fine Particle Size

37.3 Kg of darunavir ethanolate obtained as per process described inexample 1 was tangentially fed in to the circular milling chamber of thejet mill micronizer through a venturi under nitrogen at a pressure ofabout 2 Kg/cm². The milling chamber was rotated at a speed of 28 rpm atambient temperature for 3-7 hours. The smaller particles were collectedin the collection chamber.

Yield=0.99 Kg (w/w)

Particle size distribution: d_(0.9)=97 μm; d_(0.5)=18 μm; d_(0.1)=2 μm

Purity (by HPLC assay)=99.7%

Bulk density=0.42 g/ml

Tapped density=0.72 g/ml

Any other individual impurity was below detection limit (by HPLC).

1. A process for preparation of darunavir of formula (1)

comprising the steps of: (i) condensation of the amino compound offormula (4)

with furanyl derivative of formula (3)

where R=succinimidyl, p-nitrophenyl, imidazolyl, phenyl, chloro or thelike, to obtain nitro compound of formula (5);

(ii) reduction of nitro compound of formula (5) to obtain darunavir (1);and (iii) optionally converting darunavir (1) to darunavir ethanolate.2. A process according to claim 1, wherein 0.8 to 3 molar equivalents offuranyl derivative (3), most preferably 1.0 to 1.2 molar equivalents isemployed.
 3. A process according to claim 1, wherein step (i) is carriedout in a solvent selected from group consisting of lower alcohols suchas methanol, ethanol, n-propanol, isopropanol; ketones such as acetone,ethylmethyl ketone, diethyl ketone, methylisobutyl ketone; loweraliphatic esters such as ethyl acetate, methyl acetate; halogenatedhydrocarbons such as dichloromethane, chloroform dichloroethane;dimethylformamide, dimethyl sulfoxide, acetonitrile, water or mixturesthereof.
 4. A process according to claim 1, wherein step (i) is carriedout in dichloromethane.
 5. A process according to claim 1, wherein thebase employed in step (i) is selected from organic base such astriethylamine, diisopropylethyl amine, pyridine and the like or aninorganic base such as hydroxides of alkali metals or alkaline earthmetals such as sodium hydroxide, potassium hydroxide, lithium hydroxide;bicarbonates of alkali metals or alkaline earth metals such as sodiumbicarbonate, potassium bicarbonate and the like; carbonates of alkalimetals or alkaline earth metals such as sodium carbonate, potassiumcarbonate; ammonia or the like.
 6. A process according to claim 1,wherein the base employed in step (i) is triethylamine.
 7. A processaccording to claim 1, wherein molar ratio of base employed in step (i)with respect to amino compound (4) is in the range of 0.5 to 6 molarequivalents, most preferably 2 molar equivalents.
 8. A process accordingto claim 1, wherein step (i) is carried out at a temperature rangingfrom −20° C. to 100° C., most preferably at 20-30° C.
 9. A processaccording to claim 1, wherein step (ii) is carried out in a solventselected from lower alcohols such as methanol, ethanol, isopropylalcohol, ter-butyl alcohol; aliphatic esters such as ethyl acetate,methyl acetate, isopropyl acetate; amides such as dimethyl formamide;aliphatic halogenated hydrocarbons such as dichloromethane, chloroform;aromatic hydrocarbons such as benzene, xylene, toluene; ethers such asdiethyl ether, diisopropyl ether, tetrahydrofuran, 1,4-dioxane;dimethylsulfoxide, water or any mixtures thereof.
 10. A processaccording to claim 1, wherein step (ii) is carried out in ethyl acetate.11. A process according to claim 1, wherein step (ii) is carried out inpresence of a catalyst is selected from transition metal catalyst suchas palladium on carbon, PtO₂, Raney Nickel, ruthenium, rhodium; iron inacidic medium; borane complexes, diborane; borohydrides such as sodiumborohydride, lithium aluminium hydride and the like.
 12. A processaccording to claim 1, wherein step (ii) is preferably carried out bycatalytic hydrogenation in presence of transition metal catalystselected from palladium on carbon, PtO₂ and Raney nickel, mostpreferably Palladium on carbon.
 13. A process according to claim 1,wherein step (ii) is carried out at a temperature ranging from −20° C.to 100° C., most preferably at 20-30° C.
 14. A process according toclaim 1, wherein step (ii) is optionally carried out in presence of anorganic base selected from triethylamine, diisopropylethyl amine,pyridine and the like or an inorganic base selected from hydroxides ofalkali metals or alkaline earth metals such as sodium hydroxide,potassium hydroxide, lithium hydroxide; bicarbonates of alkali metals oralkaline earth metals such as sodium bicarbonate, potassium bicarbonateand the like; carbonates of alkali metals or alkaline earth metals suchas sodium carbonate, potassium carbonate; ammonia.
 15. A processaccording to claim 1, wherein step (ii) is optionally carried out inpresence of triethylamine.
 16. A process according to claim 1, whereinthe molar ratio of base employed in step (ii) with respect to nitrocompound (5) is in the range of 0.5 to 5 molar equivalents, mostpreferably 1.5 molar equivalents.